Dengvaxia is a vaccine that is designed to protect against dengue fever, a mosquito-borne viral infection that is prevalent in tropical and subtropical regions. This vaccine is the first of its kind to be approved for use in preventing dengue fever, and it has shown promising results in clinical trials.

Dengvaxia works by stimulating the immune system to produce antibodies against the dengue virus, which helps to prevent infection if a person is exposed to the virus in the future. It is recommended for individuals between the ages of 9 and 45 who live in areas where dengue fever is endemic.

As with any vaccine, Dengvaxia may cause some mild side effects, such as pain or swelling at the injection site, fever, headache, or muscle aches. These side effects are usually mild and go away on their own within a few days. In rare cases, more serious side effects may occur, so it is important to discuss any concerns with your healthcare provider before receiving the vaccine.

It is important to note that Dengvaxia is not 100% effective at preventing dengue fever, and it is still important to take precautions to avoid mosquito bites, such as using insect repellent and wearing long sleeves and pants. However, Dengvaxia can provide an additional layer of protection against this potentially serious illness.

If you have any questions or concerns about Dengvaxia, please do not hesitate to speak with your healthcare provider. They can provide you with more information about the vaccine and help you determine if it is the right choice for you.